TAO Kinase inhibitor 2

CAS No. 850467-77-5

TAO Kinase inhibitor 2( —— )

Catalog No. M36917 CAS No. 850467-77-5

TAO Kinase inhibitor 2 is a TAO kinase inhibitor with an IC50 of 50-500 nM. TAO Kinase inhibitor 2 inhibits KIAA1361 and JIK with IC50s of 50-500 nM.

Purity : >98% (HPLC)

COA Datasheet HNMR HPLC MSDS Handing Instructions
Size Price / USD Stock Quantity
2MG 46 Get Quote
5MG 65 Get Quote
10MG 107 Get Quote
25MG 174 Get Quote
50MG 260 Get Quote
100MG 377 Get Quote
500MG 858 Get Quote
1G Get Quote Get Quote

Biological Information

  • Product Name
    TAO Kinase inhibitor 2
  • Note
    Research use only, not for human use.
  • Brief Description
    TAO Kinase inhibitor 2 is a TAO kinase inhibitor with an IC50 of 50-500 nM. TAO Kinase inhibitor 2 inhibits KIAA1361 and JIK with IC50s of 50-500 nM.
  • Description
    TAO Kinase inhibitor 2 (Example 49) is a TAO Kinase inhibitor (IC50=between 50 and 500 nM). TAO Kinase inhibitor 2 also inhibits KIAA1361 and JIK with IC50s of 50-500 nM.
  • In Vitro
    ——
  • In Vivo
    ——
  • Synonyms
    ——
  • Pathway
    Apoptosis
  • Target
    Serine/threonin kinase
  • Recptor
    Serine/threonin kinase
  • Research Area
    ——
  • Indication
    ——

Chemical Information

  • CAS Number
    850467-77-5
  • Formula Weight
    400.47
  • Molecular Formula
    C25H24N2O3
  • Purity
    >98% (HPLC)
  • Solubility
    ——
  • SMILES
    N(C(CNC(=O)C1=CC=C(OC2=CC=CC=C2)C=C1)=O)C3C=4C(CCC3)=CC=CC4
  • Chemical Name
    ——

Shipping & Storage Information

  • Storage
    (-20℃)
  • Shipping
    With Ice Pack
  • Stability
    ≥ 2 years

Reference

1. Deborah Lynn Baly, et al. Tao kinase modulators and methods of use. Patent. WO2005040355.
molnova catalog
related products
  • kb-NB77-78

    kb-NB77-78 is an analog of CID797718, which is a by-product of the synthesis of the parental compound, CID755673(PKD1 inhibitor).

  • SPHINX31

    SPHINX31 is a potent inhibitor of serine/arginine-rich protein kinase 1 (SRPK1; IC50: 5.9 nM).

  • PCSK9-IN-10

    PCSK9-IN-10, a potent and orally active inhibitor of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9), exhibits a half-maximal inhibitory concentration (IC50) of 6.4 μM.